Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.

Rettinger E, Kreyenberg H, Merker M, Kuçi S, Willasch A, Bug G, Ullrich E, Wels WS, Bonig H, Klingebiel T, Bader P.

Cytotherapy. 2014 Jun;16(6):835-44. doi: 10.1016/j.jcyt.2014.01.003. Epub 2014 Feb 28.

PMID:
24582456
2.

Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.

Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, Nash RA, Aglietta M, Cignetti A.

Int Immunol. 2008 Jul;20(7):841-8. doi: 10.1093/intimm/dxn042. Epub 2008 May 9.

PMID:
18469328
3.

Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.

Durrieu L, Gregoire-Gauthier J, Dieng MM, Fontaine F, le Deist F, Haddad E.

Cytotherapy. 2012 Nov;14(10):1245-57. doi: 10.3109/14653249.2012.714864. Epub 2012 Sep 14.

PMID:
22974386
4.

Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.

Pfirrmann V, Oelsner S, Rettinger E, Huenecke S, Bonig H, Merker M, Wels WS, Cinatl J, Schubert R, Klingebiel T, Bader P.

Cytotherapy. 2015 Aug;17(8):1139-51. doi: 10.1016/j.jcyt.2015.04.011. Epub 2015 Jun 10.

PMID:
26072027
5.

Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.

Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A.

Expert Opin Biol Ther. 2009 Jul;9(7):831-40. doi: 10.1517/14712590903005552. Review.

PMID:
19463075
6.

Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.

Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1679-87. doi: 10.1016/j.bbmt.2011.05.012. Epub 2011 May 25.

7.

Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood.

Zhang Z, Zhao X, Zhang T, Wang L, Yang L, Huang L, Li F, Liu J, Yue D, Wang F, Li J, Guan F, Xu Y, Zhang B, Zhang Y.

Cytotherapy. 2015 Jan;17(1):86-97. doi: 10.1016/j.jcyt.2014.09.006. Epub 2014 Oct 24.

PMID:
25457278
9.

Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study.

Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A.

Haematologica. 2007 Jul;92(7):952-9.

10.

CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.

Wang Y, Bo J, Dai HR, Lu XC, Lv HY, Yang B, Wang T, Han WD.

Exp Hematol. 2013 Mar;41(3):241-52.e3. doi: 10.1016/j.exphem.2012.10.014. Epub 2012 Oct 30.

PMID:
23123634
11.

Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation.

Kuçi S, Rettinger E, Voss B, Weber G, Stais M, Kreyenberg H, Willasch A, Kuçi Z, Koscielniak E, Klöss S, von Laer D, Klingebiel T, Bader P.

Haematologica. 2010 Sep;95(9):1579-86. doi: 10.3324/haematol.2009.019885. Epub 2010 Apr 7.

12.

Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers.

Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Giraudo Diego L, Cammarata C, Jordaney N, Carnevale-Schianca F, Gallo S, Fagioli F, Piacibello W, Elia AR, Pignochino Y, Dell'aglio C, Grignani G, Cignetti A, Aglietta M, Sangiolo D.

J Immunother. 2012 Sep;35(7):579-86.

PMID:
22892454
14.

The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.

Rettinger E, Kuçi S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M, Klingebiel T, Fulda S, Bader P.

Cytotherapy. 2012 Jan;14(1):91-103. doi: 10.3109/14653249.2011.613931. Epub 2011 Oct 6.

PMID:
21973023
15.

Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models.

Rettinger E, Meyer V, Kreyenberg H, Volk A, Kuçi S, Willasch A, Koscielniak E, Fulda S, Wels WS, Boenig H, Klingebiel T, Bader P.

Front Oncol. 2012 Apr 9;2:32. doi: 10.3389/fonc.2012.00032. eCollection 2012.

16.

New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.

Waller EK, Boyer M.

Bone Marrow Transplant. 2000 May;25 Suppl 2:S20-4.

PMID:
10933181
17.

Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.

Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M.

Blood. 2011 Sep 22;118(12):3301-10. doi: 10.1182/blood-2011-02-336321. Epub 2011 Aug 5.

18.

Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.

Durrieu L, Lemieux W, Dieng MM, Fontaine F, Duval M, Le Deist F, Haddad E.

Cytotherapy. 2014 Jun;16(6):845-56. doi: 10.1016/j.jcyt.2013.12.010. Epub 2014 Feb 12.

PMID:
24529554
19.

In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy.

Bremm M, Huenecke S, Zimmermann O, Pfirrmann V, Quaiser A, Bonig H, Soerensen J, Klingebiel T, Rettinger E, Bader P, Cappel C.

J Transl Med. 2016 Sep 13;14:264. doi: 10.1186/s12967-016-1024-4.

20.

Inducible costimulator (ICOS) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo.

Wang J, He M, Shi W, Sha H, Feng J, Wang S, Wang Y.

Cancer Invest. 2009 Mar;27(3):244-50. doi: 10.1080/07357900802239124.

PMID:
19194830

Supplemental Content

Support Center